Clinical trial • Phase I • Musculoskeletal | Immunology
Clinical trial in Axial spondyloarthritis
Phase I trial for Axial spondyloarthritis. 48 participants.
Overview
- Trial Therapeutic Area
- Musculoskeletal | Immunology
- Trial Disease
- Axial spondyloarthritis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 02-07-2025
- First CTIS Authorization Date
- 06-10-2025
Trial design
Phase I trial across 5 sites in Belgium, Germany, Netherlands.
- Target Sample Size
- 48
Eligibility
Recruits 48 No vulnerable populations selected (isVulnerablePopulationSelected: false).
- Vulnerable Population
- No vulnerable populations selected (isVulnerablePopulationSelected: false)
Recruitment
- Planned Sample Size
- 48
- Recruitment Window Months
- 9
Geography
- Total Number Of Sites
- 5
- Total Number Of Participants
- 20
Belgium
- Earliest CTIS Part Ii Submission Date
- 17-09-2025
- Latest Decision Or Authorization Date
- 23-01-2026
- Processing Time Days
- 128
- Number Of Sites
- 2
- Number Of Participants
- 8
Sites
- Site Name
- Universitair Ziekenhuis Gent
- Department Name
- Rheumatology
- Contact Person Name
- Filip Van den Bosch
- Contact Person Email
- filip.vandenbosch@ugent.be
- Site Name
- UZ Leuven
- Department Name
- Rheumatology
- Contact Person Name
- Kurt De Vlam
- Contact Person Email
- kurt.devlam@uzleuven.be
Germany
- Earliest CTIS Part Ii Submission Date
- 22-09-2025
- Latest Decision Or Authorization Date
- 22-01-2026
- Processing Time Days
- 122
- Number Of Sites
- 2
- Number Of Participants
- 8
Sites
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Gastroenterologie, Infektiologie und Rheumatologie
- Contact Person Name
- Valeria Rios Rodriguez
- Contact Person Email
- valeria.rios-rodriguez@charite.de
- Site Name
- St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr
- Department Name
- Rheumazentrum
- Contact Person Name
- Xenofon Baraliakos
- Contact Person Email
- baraliakos@me.com
Netherlands
- Earliest CTIS Part Ii Submission Date
- 25-09-2025
- Latest Decision Or Authorization Date
- 27-01-2026
- Processing Time Days
- 124
- Number Of Sites
- 1
- Number Of Participants
- 4
Sites
- Site Name
- Amsterdam UMC Stichting
- Department Name
- Rheumatology and Clinical Immunology
- Contact Person Name
- Marleen van de Sande
- Contact Person Email
- m.g.vandesande@amsterdamumc.nl
Sponsor
Primary sponsor
- Full Name
- Grey Wolf Therapeutics Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Related trials
Other published trials that may interest you.
- INFLIXIMAB for Axial spondyloarthritis
- Risankizumab for Axial spondyloarthritis
- TECHNETIUM (99MTC) CERTOLIZUMAB PEGOL for Axial spondyloarthritis
- Allogeneic faecal microbiota, pooled for Axial spondyloarthritis
- [AL[18F]F]FAPI-74 for Fever of unknown origin (FUO) | Inflammation of unknown origin (IUO) | IgG4-related disease | Axial spondyloarthritis